secwatch.observer — SEC 8-K summary
======================================

Issuer:     Perspective Therapeutics, Inc. (CATX)
CIK:        0000728387
Form:       8-K
Filed at:   2024-05-15T23:59:59+00:00
Accession:  0000950170-24-060028
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Perspective Therapeutics reports Q1 net loss $12.3M ($0.02/sh); cash $180.6M after $177M raise
--------------------------------------------------------------------------------

- Net loss $12.3M for Q1 2024 vs $0.4M year ago; R&D expense rose 127% to $7.5M.
- Cash, equivalents & short-term investments $180.6M at March 31 vs $9.2M at Dec 31; additional $49.5M raised via ATM in April.
- Raised $177.2M gross from public/private offerings including $20.8M private placement and Lantheus investment.
- Phase 1/2a for [212Pb]VMT-α-NET dosed 9 patients; combo trial with Bristol Myers' nivolumab for VMT01 in melanoma planned.
- Disclosed new pre-IND asset PSV359 targeting FAP-α; IND expected late 2024; brachytherapy divested to GT Medical.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/728387/000095017024060028/0000950170-24-060028-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/728387/000095017024060028/catx-20240515.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-060028

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer